Desmopressin Acetate Tablet
FDA Recall NDC 23155-490
FDA Enforcement Report: View Recall Date, Reasons, and Safety Status
Active & Historical Enforcement Reports
The FDA has identified 1 recorded enforcement report(s) associated with Desmopressin Acetate (NDC 23155-490). A significant event, classified as Class II, was initiated on Nov 23, 2022 by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc.. The reported reason for this action was: "Subpotent Drug"
This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.
This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.
Reported Recall Events
Class II Terminated
Subpotent Drug
Nov 23, 2022
Dec 07, 2022
13805 Bottles each containing 100 tablets
Recall Profile & Regulatory Data
Event ID
91171
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Heritage Pharmaceuticals Inc
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide within the United States
Termination Date
Dec 13, 2023
Product Description
Desmopressin Acetate Tablets 0.2mg, 100-count bottles, RX Only, Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816, NDC 23155-490-01
Batch or Lot Expiration Information
Lot# : 220440A, Exp. Date 05/2024
Affected Packages Involved in this Recall
23155-489-01Product
23155-489-05Product
23155-490-01Product
23155-490-05Product
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
